Administering adjuvant chemotherapy to stage II colon cancer patients is controversial due to limited benefit observed for this subpopulation. Recently, Dalerba et al. (2016) identified a subgroup of stage II patients that might benefit from adjuvant chemotherapy based on lack of CDX2 expression in their cancer stem cells.
Fearon, E. R., & Huang, E. H. (2016, February 4). CDX2: Linking Cell and Patient Fates in Colon Cancer. Cell Stem Cell. Cell Press. https://doi.org/10.1016/j.stem.2016.01.011